FDA Priority Review granted for GSK’s Zejula
There are around 7,500 new ovarian cancer cases in the UK every year.
Read More
Tag: Tesaro
GSK’s endometrial cancer drug to be filed later this year
GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
Read More
GSK posts Q4 profit
GlaxoSmithKline (GSK) has released its fourth-quarter 2018 results, reporting prescription drug sales of £4.8 billion – a 6% increase on the prior year period – and profit of £1.4 billion, marking an increase of £442 million.
Read More
GSK completes Tesaro deal
GlaxoSmithKline has completed its acquisition of Tesaro, the oncology focused biopharmaceutical company.
Read More
GSK extends expiration date for Tesaro offer
GlaxoSmithKline subsidiary Adriatic Acquisition Corporation (AAC) has extended the expiration date for its tender offer for US-based Tesaro.
Read More
GSK adds to cancer offering with $5.1bn Tesaro buy
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.
Read More
NICE asks Tesaro to submit CDF application for Zejula
Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
Read More
EU approves post-chemo option for patients with ovarian cancer
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
